A process is ultimately validated to ensure which of the following?

A. The process meets the regulatory requirements.

B. The process meets the quality system requirements.

C. The process consistently produces the desired results.

D. The process consistently meets the desiredQuantity standards

Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?

A. "Product X is a guaranteed cure for arthritis."

B. "Product X is effective for the treatment of arthritis."

C. "Product X is safe for arthritis and without side effects."

D. "Product X is effective in all patients with arthritis."

After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?

A. Add a warning in the IFU.

B. Discontinue the project.

C. Perform another risk-benefit analysis.

D. Redesign the device.

A company is developing a device-drug combination product. Which of the following should be evaluated FIRST in order to determine the applicable guidance documents?

A. Approved indications of the drug

B. Determination of primary mode of action

C. Determination of product design deliverables

D. Guidance documents for the device

During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?

A. Allow doctors to use the product for the off-label indication.

B. Communicate with the sales department to stop using the promotional materials.

C. Contact the marketing department to recall the product.

D. Request that doctors stop using the product for the off-label indication.

When applying for marketing approval of a drug for a rare disease, which requirement can be waived?

A. Pre-clinical studies

B. Phase I clinical trials

C. Phase I and II clinical trials

D. Phase III clinical trials

Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?

A. Subject is hospitalized due to complications of the product administration.

B. Subject is hospitalized for the purpose of product administration.

C. Subject's hospitalization is due to an unscheduled hip operation.

D. Subject's hospitalization is prolonged during the clinical trial.

According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?

A. 3

B. 5

C. 7

D. 9

Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?

A. Fishbone analysis

B. Failure modes, effects, and criticality analysis

C. Fault tree analysis

D. Quality by design analysis

According to ICH, which of the following components of study information is NOT required in a clinical study report?

A. Randomization scheme and codes

B. Protocol and protocol amendments

C. ListoflECsorlRBs

D. Detailed CVofall investigators